Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring
暂无分享,去创建一个
Fei Huang | F. Huang | Li-an Xu | F. Lee | F. Luo | Francis Lee | K. Reeves | E. Clark | Feng R Luo | Li-An Xu | Xi-De Wang | Karen Reeves | Edwin Clark | Xi‐De Wang
[1] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[2] Fei Huang,et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.
[3] D. Louis,et al. Influence of unrecognized molecular heterogeneity on randomized clinical trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Gondi,et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. , 2006, The Journal of biological chemistry.
[5] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[6] E. Small,et al. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy , 2006, BJU international.
[7] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[8] Zhiyong Guo,et al. Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.
[9] A. Jemal,et al. Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.
[10] N. Leslie,et al. Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters. , 1990, The Journal of biological chemistry.
[11] S. Ben‐Sasson,et al. Lyn Is a Target Gene for Prostate Cancer , 2004, Cancer Research.
[12] H. Miyake,et al. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. , 1999, International journal of oncology.
[13] Rajvir Dahiya,et al. Hormonal, cellular, and molecular control of prostatic development. , 2003, Developmental biology.
[14] J. Dering,et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro , 2007, Breast Cancer Research and Treatment.
[15] C. Sweep,et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.
[16] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[17] J. Isaacs,et al. A history of prostate cancer treatment , 2002, Nature Reviews Cancer.
[18] E. Lander,et al. Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.
[19] Michael Castro. The simpleton's error in drug development. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] G. Karsenty,et al. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft , 2004, Oncogene.
[21] Yong Li,et al. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. , 2006, Human pathology.
[22] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[23] D. Bostwick,et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer , 1999, The Prostate.
[24] C. Korch,et al. Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.
[25] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Timothy J. Yeatman,et al. A renaissance for SRC , 2004, Nature Reviews Cancer.
[27] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[28] J. Isaacs,et al. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. , 2006, Cancer research.
[29] E. Small,et al. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. , 2007, Clinical genitourinary cancer.
[30] M. Delorenzi,et al. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[32] T Visakorpi,et al. Molecular genetics of prostate cancer. , 2001, Annals of medicine.
[33] S. Parsons,et al. c-Src and cooperating partners in human cancer. , 2004, Cancer cell.
[34] H. Li,et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells , 2006, Oncogene.
[35] R. Tibshirani,et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[36] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[37] F. Bertucci,et al. Gene expression profiling of breast cell lines identifies potential new basal markers , 2006, Oncogene.
[38] Stephen C. Harris,et al. Rat toxicogenomic study reveals analytical consistency across microarray platforms , 2006, Nature Biotechnology.
[39] C. Roehrborn,et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Sheila M. Thomas,et al. Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.
[41] J. Cheng,et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. , 2005, Cancer research.